PHASEII Study of S-1 with Irinotecan Combination Therapy for EGFR-Mutated NSCLC Resistant to EGFR-TKI: NJLCG0804

Backgroud: Basic experiments showed high sensitivity offluoropyrimidine agent to EGFR-TKI resistant cell-line and the synergistic effect of S-1 (a novel oral fluorouracil derivative) and irinotecan combination. We therefore conducted a phase II trial to evaluate the efficacy and safety of S-1 and irinotecan combination for EGFR-mutated NSCLC resistant to both platinum-based chemotherapy and EGFR-TKI. Methods: Eligible patients (pts) had NSCLC with EGFR mutation, ECOG performance status (PS) 0 to 1, failure of EGFR-TKI following one or two